Tiantom is a biopharmaceutical research and development professional. He brings to Ridgeline expertise in translational and clinical research as well as development program leadership.

Tiantom joined Ridgeline in 2020 from MorphoSys where he assumed leadership positions as Senior Global Program Medical Director and Global Program Head having been responsible for the clinical development of several biologics compounds in the hemato- and immuno-oncology space as well as the autoimmune therapeutic area. He previously held R&D positions at Roche including Site Head of Translational Research Sciences in Shanghai.

Tiantom is a licensed M.D. and earned his medical degree at the University of Lübeck (Germany).